Biovian, a specialised contract development and manufacturing organisation (CDMO) focusing on biopharmaceuticals, has announced a significant investment exceeding €50m to expand its existing manufacturing facility in Turku, Finland.

The upcoming facility will span an impressive area of 6,400m². It will be equipped with the latest machinery and advanced technologies to support the development, production, and testing of Advanced Therapy Medicinal Products (ATMP), such as adenoviral and adeno-associated viral (AAV) therapies.

Among its features, the new facility will include dedicated Class A to D cleanroom areas, facilitating the production of bulk drug substances and the final drug products.

To ensure the delivery of safe, reliable, and compliant biopharmaceuticals, the expanded facility will adhere to the rigorous current good manufacturing practices (cGMP) and meet both EU and US GMP requirements.

This strategic investment reflects Biovian’s commitment to meeting the growing demand for high-quality biopharmaceutical manufacturing services. It further solidifies Biovian’s reputation as a trusted partner in the biopharmaceutical industry. Together with its existing manufacturing facility, the new premises will bring the total area of Biovian’s operations to 11,500m².

By expanding its capabilities, Biovian will be better positioned to take on larger-scale viral vector and microbial protein projects and run concurrent manufacturing campaigns. The increased production capacity and flexibility will complement their existing manufacturing facilities in the area.

The expansion project is slated for completion in December 2024, and the new facility is expected to be fully operational by 2025. This substantial investment is projected to generate 100 job opportunities in the region, adding to Biovian’s current workforce of approximately 200 skilled team members.

Biovian CEO Antti Nieminen said: “The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland and most of all provide vital therapies to patients suffering from today’s untreatable diseases.

“Biovian aims to facilitate swift drug development and delivery, reducing time-to-market for its customers, all while creating an enjoyable experience. The new manufacturing facility will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein.

“When the new site is up and running, our existing capacity will be transformed into new microbial protein suites. Thus, both microbial and viral vector customers will benefit from this expansion.”